abstract |
The present invention relates to an anticancer hybrid exosome composition using amphiphilic doxorubicin and exosomes. In the present invention, a hybrid exosome formulation (Lexobrid A) was prepared by mixing lipid-conjugated doxorubicin and exosomes. The Lexobrid A can increase the residence time and half-life in cancer cells, improve bioavailability, and increase the anticancer effect by slowly releasing doxorubicin in the environment around cancer cells in the body (pH 5.5). Therefore, the hybrid exosome of the present invention can exhibit a lasting anticancer effect, and thus can be usefully used as a composition for drug delivery. |